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Abstract
Background: Therapeutic adherence of patients with chronic obstructive pulmonary disease (COPD) is poor. It is
therefore necessary to determine the magnitude of non-adherence to develop strategies to correct this behaviour.
The purpose of this study was to analyse the diagnostic validity of indirect adherence methods.
Methods: Sample: 195 COPD patients undergoing scheduled inhaled treatment attending 5 Primary Care Centres
of Malaga, Spain. Variables: Sociodemographic profile, illness data, spirometry, quality of life (St. George Respiratory
Questionnaire: SGRQ), and inhaled medication counting (count of dose/pill or electronic monitoring) were
collected. The patient’s knowledge of COPD (Batalla test:BT),their attitude towards treatment (Morisky-Green test:
MGT) and their self-reported therapeutic adherence (Haynes-Sackett test: HST) were used as methods of evaluating
adherence. The follow-up consisted four visits over one year (the recruitment visit: V0; and after 1 month:V1;
6 months:V2; and 1 year:V3).
Results: The mean age was 69.59 (95% CI, 68.29-70.89) years old and 93.8% were male. Other findings included:
85.4% had a low educational level, 23.6% were smokers, 71.5% mild-moderate COPD stage with a FEV1 = 56.86
(SD = 18.85); exacerbations per year = 1.41(95% CI, 1-1.8). The total SGRQ score was 44.96 (95% CI, 42.46-47.46),
showing a mild self-perceived impairment in health. The prevalence of adherence (dose/pill count) was 68.1% (95%
CI, 60.9-75.3) at V1, 80% (95% CI, 73-87) at V2 and 84% (95% CI, 77.9) at V3. The MGT showed a specificity of
67.34% at V1, 76.19% at V2 and 69.62% at V3. The sensitivity was 53.33% at V1, 66.66% at V2 and 33.33% at V3.The
BT showed a specificity of 55.1% at V1, 70.23% at V2 and 67.09% at V3. The sensitivity was 68.88% at V1, 71.43% at
V2 and 46.66% at V3. Considering both tests together, the specificity was 86.73% at V1, 94.04% at V2 and 92.49% at
V3 and the sensitivity was 37.77% at V1, 47.62% at V2 and 13.3% at V3.
Conclusions: The prevalence of treatment adherence changes over time. Indirect methods (dose/pill count and
self-reported) can be useful to detect non-adherence in COPD patients. The combination of MGT and BT is the
best approach to test self-reported adherence.
Background
Chronic obstructive pulmonary disease (COPD) is cur-
rently the fourth leading cause of death world-wide.
Furthermore, the prevalence of COPD is increasing and
it is estimated that by 2020 COPD will be the third
leading cause of death [1,2].
Important progress has been made in the pharmacolo-
gical and non-pharmacological treatment of COPD.
While a major goal of therapy is to provide symptoms
relief, only the effective management of COPD has been
shown to reduce the rate of exacerbations, hospitalisa-
tions and mortality and to improve health-related qual-
ity of life [3]. The effectiveness of treatment relies on
patient agreement with adherence to the therapy regime.
As with all chronic diseases, non-adherence in patients
with COPD is common and contributes to adverse
* Correspondence: mariap.barnestein.exts@juntadeandalucia.es
1Family and Community Medicine Teaching Unit of Malaga. Health District
Malaga. Málaga, Spain
Full list of author information is available at the end of the article
Barnestein-Fonseca et al. BMC Pulmonary Medicine 2011, 11:6
http://www.biomedcentral.com/1471-2466/11/6
© 2011 Barnestein-Fonseca et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.health outcomes, reduced quality of life and increased
healthcare expenditure [4]. According to the World
Health Organization, patient adherence to long-term
therapy averages 50% [5]. In the Lung Health Study [6],
therapeutic adherence with inhaled treatment recorded
by self-reported methods after one year of follow-up
was 60%, decreasing to 50% after five years of follow-up.
Different types of non adherence exist in COPD
patients [7], including underuse (a reduction in the
apparent daily use versus the standard dose of a medica-
tion that is indicated for the treatment or prevention of
a disease or condition), overuse (use of higher than pre-
scribed treatment doses, or shorter intervals between
doses), improper or inappropriate use (the drug is inef-
fective, not indicated or if there is unnecessary duplica-
tion of therapy).
The most common type of non-adherence in COPD
patients is underuse [8], and improper use is the most
frequent type of non-adherence in patients older than
65 years of age with polypharmacy. In COPD, underuse
is followed in frequency by overuse and improper use of
the medication-delivering device. Underuse can be spora-
dic or systematic, from forgetting an occasional dose to
changing dosing schedules; patients with underuse are at
a higher risk for adherence-related morbidity [7].
Several methods exist to measure adherence in COPD,
each with its own strengths and limitations. Biochemical
evaluation of drug level can confirm the intake. How-
ever, this method is both expensive and invasive and
can also reflect other factors, resulting in pharmacoki-
netic variations [9]. Electronic monitors are increasingly
being used in clinical trials to measure adherence. They
provide accurate and reliable records of dosage but are
expensive, subject to malfunction and cannot confirm
ingestion [10]. Other common methods to measure
adherence include patients’ diaries, pill counts, canister
weighing and analysis of computerized pharmacy
records, but these can overestimate adherence [11]. Pill
count is limited to oral medications and only assesses
whether the correct number of pills have been removed,
it does not indicate ingestion, dose or dose frequency.
However, this method is simple, available and useful in
daily clinical practice as an approach to measuring
adherence. Likewise, canister weighing is not reliable
because activation of the device immediately prior to
the visit can suggest adherence. Analysis of pharmacy
records provides evidence of drug refill patterns but
cannot assess ingestion or pattern of use [3].
The easiest approach to assessing adherence is to sim-
ply query the patient, but this method generally overes-
timates medication use [4,12]. Physician assessment of
their patients’ adherence is similar [13]. In the clinical
setting, therefore, reliance on any single method of
assessment can be misleading.
On the other hand, patients who are not adherent and
who are aware of this behaviour are those who are
going to respond better to health educational policies.
So, it is necessary to identify them properly and this
would probably allows us to form patients groups more
effectively for future educational interventions.
Nevertheless, it is still necessary to determine the
magnitude of non-adherence in COPD patients as the
first step towards developing strategies to correct these
behaviours.
The objective of this study was to asses the diagnostic
validity to estimate the prevalence of non-adherence in
COPD patients with inhaled medication using three self-
reported methods that could be useful and easy in clini-
cal practice, considering the electronic monitoring or
the pill count as the reference method.
Methods
A cohort study was undertaken in 5 Health Care Center
in Málaga Province. The subjects were COPD patients
and with a medical records contained data about the
diagnosis and treatment of their disease. The recruit-
ment period was six months and the follow-up period
was one year (Figure 1). The inclusion criteria were: a
diagnosis of COPD in the patient’s clinical record, tak-
ing scheduled inhaled therapy, and belonging to the
basic health care area. The exclusion criteria were:
patients with any respiratory condition not included in
the definition of COPD (bronchiectasis, asthma or cystic
fibrosis) and patients with cognitive impairment.
The protocol and the patient information form were
approved by a primary care ethics committee, and all
the patients signed informed consent forms before their
inclusion in the study.
We calculated the sample size according to the follow-
ing data: (1) a prevalence of non-adherence using the
MGT of 65%, found in a previous study of a cohort of
COPD patients performed by our group (data not pub-
lished); (2) 95% confidence level; (3) 7% precision and
(4) 35% of expected losses. The final sample size was
calculated to be 237 participants, who were then
selected by a non-probabilistic sampling method.
Sociodemographic variables (age, sex, civil status, educa-
tional level); Body mass index (BMI); COPD-related vari-
ables (smoking habits, number of cigarettes, treatment and
exacerbations); forced spirometry according to the SEPAR
guidelines [14]; comorbidity and quality of life using the St
George Respiratory Questionnaire (SGRQ). The Spanish
version of the SGRQ [15,16] is a specific instrument for
measuring quality of life in patients with respiratory dis-
ease. It has 50 items divided into three scales: symptoms
(frequency and severity of respiratory symptoms), activity
(activity limitations due to dyspnoea) and impact (psycho-
logical and social disorders due to respiratory disease).
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Page 2 of 10SGRQ scores range from 0-100, with zero indicating no
impairment in quality of life. The SGRQ can be applied by
a self-administered way or it can be read to the subject if
he has reading impairments. We selected the second way
because of the low social and cultural level of the study
group.
Adherence
Adherence to (or compliance with) a medication regi-
men is generally defined as “t h ee x t e n tt ow h i c hap e r -
son’s behaviour -taking medication, following a diet
and/or executing lifestyle changes- corresponds with
agreed recommendations from a health care provider”
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Excluded 
N = 1294 
687 non current, scheduled or 
measurable  treatment  
273 Asthma/other respiratory 
pathologies  
170 without clinical records/without 
access to records 
105 without a diagnose in Diraya 
(informatics data system). 
 27 non registered phone number 
 14 Cognitive Impairment 
 11 Disable 
 3 unwilling  
 2 Deceased 
 1 Social risk 
 1 discharged to a general practice 
non participant in the trial 
Losses   N = 481 
121 unreachable 
106 non current, scheduled or 
measurable  treatment 
  78 non registered or incorrect 
phone number  
  75 unwilling 
  46 disable 
  22 deceased 
  11 do not attend appointment 
  11 unable to attend 
    3 hospitalized 
    3 cognitive impairment 
    2 alcoholism 
    2 non COPD 
    1  discharged  to  a  general 
practice non participant in study 
677 follow 
Inclusion criteria 
Participants  
n = 195 
Visit 1 after one month  
n = 195 
(contacted) 
COPD patients included in the archives of 5 general practices 
                             n = 1971 patients 
Visit 2 after 6 months  
n = 191 
(contacted) 
Visit 3 after one year 
n=178 
(contacted) 
160 attend to visit 1 
31 do not attend  
   - 13 unreachable 
   - 10 do not attend appointment 
   - 5 disabled 
   - 3 unable to attend 
4 unwilling to continue 
124 attend to visit 2 
53 do not attend  
   - 20 unreachable 
   - 21 do not attend appointment 
   - 4 disabled 
   - 5 unable to attend 
   - 2 hospitalized 
   - 1 impossible to measure adherence 
13 unwilling to continue 
108 attend to visit 2 
53 do not attend  
   - 29 unreachable 
   - 15 do not attend appointment 
   - 6 disabled 
   - 3 unable to attend 
17 unwilling to continue 
Figure 1 Study general graphic.
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Page 3 of 10[17]. Adherence to inhaled therapy was measured by
dose/pill count or electronic monitoring. This was con-
sidered to be the reference method, and was performed
at an unexpected appointment at the health centre. An
electronic dose counter (DOSER [18]) was used to
recount the metered dose inhaler (MDI) devices, and
doses or pills were counted in the other inhaler devices.
Adherence was measured as the number of pills or
doses taken divided by the number of pills or doses pre-
scribed, multiplied by 100 (expressed as a percentage).
In accordance with Sackett et al. [19] recommendations,
a good adherence is considered when the result of
counting is between 80% (20% loss of doses/pills) and
110% (the patient consumes 10% more doses/pills) of
doses/pills prescribed. This cutoff point was selected for
consistency with other studies [20].
Self-reported adherence methods
Three self-reported methods were selected to evaluate
treatment adherence: the Haynes and Sackett method
[21], the Morinsky Green test [22] and the Batalla test
[23]. These questionnaires to assess adherence are nor-
mally used for chronic conditions and have been
adapted and validated for the Spanish population for
conditions such as hypertension and hyperlipidaemia
[24,25].
Haynes and Sackett method (HST)
Self-reported assessment of adherence was introduced in
the following sentence: “People often have difficulty tak-
ing their pills for one reason or another and we are
interested in finding out any problems that occur so
that we can understand them better.” Patients were then
asked whether they ever missed their pills and, if so, to
state their current prescriptions and the average number
of tablets missed per month [19]. Good adherence was
considered to be when the percentage of doses taken
was between 80% and 110% of the prescribed dose.
Morinsky Green test (MGT)
We measured the attitude towards treatment using the
MGT [22], adapted by us for use with inhaled medica-
tion: (1) Do you ever forget to take your inhaled medi-
cation? (2) Are you careless at times about taking your
inhaled medication? (3) When you feel better, do you
sometimes stop taking your inhaled medication? (4)
Sometimes, if you feel worse when you take the inhaled
medication, do you stop taking it? We considered good
adherence to be when all four questions were answered
suitably.
Batalla test (BT)
The BT provides information about the patients’ under-
standing of their illness [23]. The questions, adapted to
COPD, used in this study were as follows: (1) Is COPD
a lifelong disease?, (2) Can you control this disease by
quitting smoking and/or with medication?, (3) Mention
one or more organs that can get damaged by COPD.
We considered good adherence to be when the patient
was able to answer these three questions suitably.
Recruitment and follow-up
Each Health Care Center provided the list of patients
included in the COPD Health Program. Once we identi-
fied the possible candidates, they were invited by phone
to participate in the study and given an appointment at
their primary health care centre. At this appointment
(recruitment visit: V0) we gave the patients a fuller
explanation of the study and they signed the informed
consent form prior to inclusion. After inclusion we mea-
sured all the study variables.
In addition, at this first visit we provided the patients
with a new MDI with an electronic dose counting device
or a new device for pill/dose count, and the patients
were told they would be phoned again for review but
they were not told when this would take place. The
patients were given another appointment after one
month (V1) and the treatment adherence was evaluated
by electronic monitoring or pill/dose count along with
the self-reported adherence tests.
The participants were again contacted five months
after the first visit and a new MDI with a dose counting
device or a new device for pill/dose count was provided.
The count was done one month later (6m o n t h sv i s i t :
V2), along with self-reported adherence tests. We also
measured other variables changes.
Finally, 11 months after starting the study, the patients
were given an appointment in order to receive another
new counting device, which was read the following
month (one year visit: V3), along with self-reported
adherence tests, forced spirometry, SGRQ and measure-
ment of the other variables.
Statistical analysis
A descriptive analysis was made of all the study vari-
ables, calculating the mean, median, standard deviation,
total frequency and relative frequency of each category;
95% confidence intervals were calculated for the means
and proportions. We considered dose/pill count to be
the reference method for assessing adherence. We per-
formed two types of analytical strategies [26] to compare
the reference value and the self-reported methods in
order to evaluate their validity to diagnose adherence:
1) open comparison to explore the existence of a statis-
tical association between each self-reported question-
naire and the reference method using the Chi-square
test, and 2) hierarchy comparison in which we assumed
that the reference method is the best method to assess
non therapeutic adherence, and we then calculated the
kappa value (as a measure of agreement between the
reference method and each self-reported test), the basic
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Page 4 of 10diagnostic descriptors (sensitivity and specificity) and
their combination (likelihood ratio) for each of the self-
reported methods. To achieve this we elaborated 2 × 2
tables and calculated the following indicators of diagnos-
tic validity for each test: Sensitivity = true positive/(true
positive+false negative); Specificity = true negative/(true
negative+false positive); Positive likelihood ratio = sensi-
tivity/(1-specificity); Negative likelihood ratio = (1-sensi-
tivity)/specificity. The data analysis was carried out
using the statistical package SPSS/PC, version 15.0.
Results
Sample characterization
Baseline
The main reasons for losses were, firstly, the difficulties
experienced in the review of the clinical records; the
clinical records of 1971 COPD patients were reviewed
but we found many false positive COPD diagnoses as
well as other respiratory conditions classified as COPD.
Secondly, the strict inclusion criteria used in this study,
such as the use of inhalers with a dose counter or that
could use a DOSER device. In addition, we were unable
to contact many patients and others refused to partici-
pate in the study (Figure 1).
The final sample consisted of 195 patients with a
diagnosis of COPD (Table 1), predominantly male
(93.8%), with a mean age of 69.59 years (95% CI,
68.29-70.89 years), and with a low educational level
(50% with no studies). At the time of the study, 23.6%
were active smokers, with a mean of 17.52 cigarettes
per day (95% CI, 14.34-20.7) and many were over-
weight [mean BMI 29.55 (95% CI, 28.87-30.23)]. Con-
cerning the COPD severity stage, 71.5% were classified
as mild to moderate, with a mixed spirometric pattern
(62.5%), and a mean FEV1 of 56.86 (SD:18.85). More
than half the patients had experienced at least one
exacerbation in the last year [mean exacerbations 1.41
(95% CI, 1-1.8)].
Drug therapy The treatment prescribed for their condi-
tion is shown in Figure 2 (represented as the percentage
of patients receiving a particular treatment). We see
that 92.8% of the patients were taking anticholinergic
drugs, 47% short-acting and 74% long-acting, prescribed
either individually or jointly according to the cases.
Beta-2 agonists were prescribed for 86.2% of the
patients, 68.45% of these were short-acting and 77.38%
long-acting. Inhaled corticosteroids were prescribed for
68.7% of the patients, in most cases combined with a
beta-2 agonist. Figure 2 also provides information about
the other drugs. Most patients (89.6%) were prescribed
combined therapy from more than one pharmacological
group. The most frequent treatment was the combina-
tion of 3 groups (46.6%): an anticholinergic drug with a
long-acting beta-2 adrenergic agonist and an inhaled
corticosteroid.
Quality of life The SGRQ scores were: symptoms scale,
46.03 (95% CI, 43.25-48.81); activity scale, 61.2 (95% CI,
58.15-64.25); impact scale, 35.34 (95% CI, 32.56-38.12);
and total score, 44.96 (95% CI, 42.46-47.46).
Adherence measures Self-reported methods were also
used at the first inclusion visit, observing variability in
the outcomes. This enabled us to determine that the
percentage of patients with good adherence was 99.5%
with the HST, 55.9% with the BT, and 52.1% with
the MGT.
2,1
5,6
14
14,4
68,7
86,2
92,8
0 1 02 03 04 05 06 07 08 09 0 1 0 0
Oral corticoids
Oxigen-therapy
Mucolytics
Xantines
Inhaled corticoids
Beta 2 agonists
Anticholinergics
Figure 2 Prescribed treatment for COPD patients (numbers in
bars expressed percentage of patients with the indicated
therapeutic group prescribed).
Table 1 Sociodemographic and clinical profile
Number of subjects 195
Gender
Male 93.8%
Age (mean, 95% CI) 69.59 (68.29-70.89)
Education levels
Without education 50%
Primary education 35.4%
Secondary education 9.4%
Higher education 4.7%
Civil Status
Single 3.6%
Married 85.6%
Widowed 8.7%
BMI (mean, 95% CI) 29.55 (28.87-30.23)
Smoking habits
Non smokers 7.2%
Smokers 23.6%
Ex smokers 69.2%
N° exacerbations (mean, 95% CI) 1.41 (1-1.8)
N° visits at PCC 4.78
N° visits due to COPD 2.06
IC: Confidence interval.
PCC: Primary Care Center.
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V1: 160 patients (82%) out of the 195 included in the
study attended the first control visit one month after
inclusion. The losses at follow-up and their reasons are
shown in Figure 1. Of the 160 patients evaluated, 13
changed their therapeutic procedure, using inhalers
when needed with no scheduled treatment; these
patients were thus excluded from the analysis. A change
in prescription occurred in 8.1% of the patients, half of
them due to addition of another medicine, mostly
because of an exacerbation or a cold, and 37.27%
because of a dose modification. At least one exacerba-
tion in the month following the inclusion visit was
experienced by 18.8% of the patients.
V2: 124 (63.5%) out of the 195 included in the study
attended the second control visit after 6 months
(Figure 1). Of the 124, eight changed their therapeutic
procedure, using inhalers when needed with no sched-
uled treatment; these patients were thus excluded from
the analysis. A change in treatment was made for 26.2%
of the patients, 40.45% due to the addition of a new
drug and 34.35% due to a dose change. At least one
exacerbation in the 6 months following the inclusion
visit was experienced by 31.7% of the patients.
V3: 108 (55.4%) out of the 195 included in the study
attended the third control visit one year after inclusion
(Figure 1). Of the 108, 38.6% experienced a change in
their prescription, most frequently concerning the addi-
tion of a new drug (26.68% of the cases), followed by a
dose change (21.24%) and total treatment renewal
(13.21%). At least one exacerbation since the previous
follow-up visit was experienced by 35.7% of the patients.
Treatment adherence V1: Adherence prevalence using
the reference method was 68.1%. When we assessed the
self-reported adherence methods, these were 100% for
the HST, 60.8% for the MGT and 46.9% for the BT.
The MGT detected 24 of the 45 patients classified as
non-adherent by RM method, while the BT found 31.
Considering both tests together, 38 out of the 45 non-
adherent patients were detected. The chi-square test
showed a significant association between the reference
method and the self-reported methods (Table 2). The
measure of agreement by kappa (k) between MGT and
the reference method was 0.194 (p = 0.019), for the BT
k = 0.194 (p = 0.011), and when we considered both
tests together k = 0.143 (p = 0.019).
V2: We observed an adherence prevalence of 80%
evaluated by the reference method and of 100%, 67.7%
and 61.9% for the HST, the MGT and the BT. The
MGT detected 14 of the 21 patients with non-adher-
ence, while the BT found 15. Considering both tests
together, 19 out of the 21 patients with non-adherence
were detected. The chi-square test showed a significant
association between the reference method and the self-
reported methods (Table 2). The measure of agreement
by kappa (k) between MGT and the reference method
was 0.348 (p = 0.001), for the BT k = 0.311 (p = 0.001)
and when we considered both tests together k =0 . 2 5 5
(p = 0.001).
V3: We observed an adherence prevalence of 84%
evaluated by the reference method. When we assessed
the indirect adherence methods, these were 100%
for the HST, 64.1% for the MGT and 64.9% for the BT.
The MGT detected 5 of the 15 patients with non-
adherence, while the BT found 7. Considering both tests
together, 10 out of the 15 patients with non-adherence
were detected. The chi-square test showed no significant
association between the reference method and the self-
reported methods at this visit (Table 2). The measure of
agreement by kappa (k) between MGT and the reference
method was 0.021 (p = 0.82), for the BT k = 0.093 (p =
0.30) and when we considered both tests together k =
0.053 (p = 0.43).
Figure 3 shows the course of inhaled treatment adher-
ence over time. We can see an increase of adherence
along the study in all indirect methods used.
Table 3 shows the diagnostic validity characteristics of
the two adherence evaluation methods.
Discussion
The diagnostic instruments [27] used in medicine have
traditionally been considered as a mean to reduce diag-
nostic uncertainty. This uncertainty reaches important
levels if we are trying to diagnose an entity such as
treatment adherence, which is influenced by a great
diversity of factors. As treatment adherence has to be
quantified with the best test available, it is necessary to
evaluate which methods are most suitable for clinical
Table 2 Open comparison of adherence prevalence between the self-reported methods and the reference method by
the chi-square test
1 month 6 months 12 months
Dose/pill count 68.1% (60.9-75.3) 80% (73-87) 84%(77-90)
Morinsky-Green Test 60.8% (53.3-68.3) p = 0.019 67.6% (59.4-75.8) p < 0.001 69.1% (60.4-77.8) p = 0.820
Batalla Test 46.9% (39.2-54.6) p = 0.011 61.9% (53.4-70) p < 0.001 64.9% (55.9-73.9) p = 0.306
Morinsky-Green Test + Batalla Test 28.7% (21.7-35.7) p = 0.002 43.8% (35.1-52.5) p < 0.001 42.6% (33.6-51.6) p = 0.633
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tic validity [24,25], selecting a reference method that
should be considered as a gold standard.
I nt h ec u r r e n ts t u d yw ea i m e dt or e v i e wa l lt h e s e
points, centred on patients included in COPD care pro-
grams in general practice setting. The first difficulty
encountered was the high percentage of patients
included in the COPD records with an incorrect diagno-
sis or the lack of data necessary to locate the patients.
These situations accounted for most of the losses at the
start, as well as during the monitoring period of the
trial. Nevertheless, no significant differences were found
between the losses and those who were included, so we
can conclude that the main effect of these losses is
probably related with statistical power. The final study
sample was similar to that described by others, except
for a higher mean age and a lower educational level
[28,29]. We still have a high prevalence in male sex
probably due to the smoking habit in our area. Patients
with mild to moderate COPD stages are predominant in
the sample because SEPAR guidelines [30] recommend
the management of these patients at primary care set-
ting and the management of patients with severe and
very severe COPD by the Neumologist. Patients with
mild-moderate COPD predominated in our sample,
most of them receiving medical treatment with anticho-
linergic and beta-2 agonist drugs, as recommended at
this stage of the disease [30,31].
By telephoning the patient unexpectedly one day
before the appointment at the health centre to review
adherence we attempted to avoid any behavioural
changes that could affect treatment adherence in the
days before the appointment.
For patients with chronic diseases seen in the primary
care setting, the dose/pill count or electronic monitoring
at the general practice have been used as the reference
method to define the diagnostic validity of the self-
reported methods [24,25,32-34], although it was found
that 22% of patients with hypertension who opened the
electronic monitoring (EM) containers did not take suf-
ficient drugs and 35% who seemed to take their pills did
not open the EM container as frequently as prescribed
[33]. The main disadvantage of this method is that it
assumes that every missing dose/pill from the package
has been taken by the patient. Accordingly, we can con-
sider that it overestimates the prevalence of treatment
adherence. However, the dose/pill count and EM are
simple, available and less expensive than others meth-
ods. This is why we used the dose/pill count as the
reference method in our study. No perfect reference
method (gold standard) exists owing to the nature of
the process that we are studying, so we assume we have
made the imperfect gold standard bias [26]. The use of
an electronic counter for MDI in COPD is usual [3,4,6],
but in fact the measure of adherence is more frequently
obtained by self-reported methods [3,7].
The adherence prevalence in our study, with the dose/
pill count, was similar to that found in other studies
[35-37], although in these studies the measure of adher-
ence was made by different methods: canister weight
[35], pharmacy database medication refill [36], or self-
reported methods [37]. We detected an improvement on
adherence prevalence over time that could be explained
by two features. The first is the Hawthorne effect along
the study (ie, tendency of subjects participating in a
research study to change their behaviour). Although this
could affect overall estimates of adherence, the implica-
tions might be less important in comparing results of
different measurements tools (unless, of course, the
effect is differentially captured by each measurement
tool); furthermore, it is difficult to perceive that any
potential Hawthorne effect would be maintained over
the many months of study. The second one is related
with a sample self-selection, where the better adherent
patients were who continued in the study over time.
Three instruments were selected in the present study
as methods of evaluating self-reported of adherence.
These methods have been validated in chronic disorders
other than respiratory diseases [24,25,33,34].
Comparison of the prevalence found using the refer-
ence method with the estimates of the self-reported
methods shows that self-reported adherence using the
HST overestimated the adherence percentage, while the
MGT and the BT produced lower compliance values.
Although self-reported compliance using the HST has
shown an adequate diagnostic validity in other trials
w i t hc h r o n i cp a t i e n t s[ 2 3 , 2 4 ] ,i no u rC O P Ds t u d yi t
overestimated adherence and showed no changes over
time (as can be seen in Figure 3), since it classified as
0
20
40
60
80
100
RM 68,1 80 84
MGT 60,8 67,6 69,1
BT 46,9 61,9 64,9
MGT+BT* 28,7 43,8 42,6
HST 100 100 100
1 months 6 months 12 months
Figure 3 Evolution of the adherence treatment percentage
after one year of monitoring. %patients. RM: dose/pill count;
MGT: Morinsky-Green Test; BT:Batalla test;HST: Haynes- Sackett Self-
report. * Adherent patients diagnosed by both methods.
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Page 7 of 10adherent 100% of the patients at all three evaluations
made. Therefore, we do not consider it suitable to use
for this disease.
The open comparison of adherence prevalence
between the self-reported methods and the reference
method (Table 2) shows a significant association (p <
0.05) at V1 and V2. No significant association was seen
at V3, possibly due to the low number of non-adherent
patients.
In order to determine the suitability of the other two
methods, we measured their agreement by kappa. The
agreement between the reference method and the self-
reported methods was poor at V1 (k = 0.143-0.194) and
fair at V2 (k = 0.255-0.348). Thus, although there is
agreement between the two measures of adherence, the
concordance was low. However, no kappa value can be
universally regarded as indicating good agreement, and
this value cannot substitute clinical judgement [38].
Table 3 Diagnostic validity of self-reported methods to detect non adherent patients with the prescribed treatment
VISIT 1 VISIT 2 VISIT 3
Non adherence (reference method) 31.9% 20% 16%
Morisky-Green Test
Non adherence 39.2% 32.4% 30.9%
Sensitivity 53.33% (38.76-68) 66.66%(46.66-86.66) 33.33%(10.3-56.3)
Specificity 67.34% (58.06-76.62) 76.19% (67-85.3) 69.62%(59.6-79.6)
Positive Predictive Value 42.86% 41.17% 17.24%
Negative Predictive Value 75.86% 90.14% 84.61%
Positive Likelihood Ratio 1.66 2.79 1.09
Negative Likelihood Ratio 0.69 0.43 0.95
Batalla Test
Non adherence 53.1% 38.1% 35.1%
Sensitivity 68.88%(55.36-82.4) 71.43%(52.1-90) 46.66%(21.6-71.66)
Specificity 55.1%(45.3-64.9) 70.23%(60.5-80) 67.09%(57.09-77.09)
Positive Predictive Value 40.79% 37.5% 21.21%
Negative Predictive Value 85.07% 90.77% 86.88%
Positive Likelihood Ratio 1.53 2.38 1.41
Negative Likelihood Ratio 0.56 0.4 0.79
MGT-BT
1- (non.adherent at least by one of two methods)
Non adherence 71.3% 56.2% 57.4%
Sensitivity 84.44%(74-95) 90.47%(78.47-100) 66.66%(56.66-76.66)
Specificity 34.69%(25.3-44.1) 52.38%(42.38-62.38) 44.3%(34.3-54.3)
Positive Predictive Value 37.25% 32.2% 18.51%
Negative Predictive Value 82.92% 95.6% 87.5%
Positive Likelihood Ratio 1.29 1.89 1.19
Negative Likelihood Ratio 0.45 0.18 0.75
MGT-BT
2- (non-adherent by the two methods)
Non adherence 21% 14.3% 8.5%
Sensitivity 37.77%(23.6-52) 47.62%(26.6-68.6) 13.3%(0-30)
Specificity 86.73%(80-93.4) 94.04% (89-99) 92.49%(86.6-98.2)
Positive Predictive Value 56.66% 66.66% 25%
Negative Predictive Value 82.52% 87.77% 84.88%
Positive Likelihood Ratio 2.84 7.98 1.77
Negative Likelihood Ratio 0.71 0.55 0.93
Morinsky-Green Test : MGT; Batalla Test:BT; Sensitivity : S ; Specificity : E ; Positive Probability Ratio: PPR.
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of subjects in each category [38]. In our case this char-
acteristic of kappa was very important because of the
great difference between the proportion of adherent and
non-adherent subjects during the follow-up. At V1 and
V2 the proportion difference was 2:1, but at V3 this dif-
ference was more than 4:1. In this situation the calcu-
lated kappa value can be misleading and we have to
consider the clinical context for its interpretation.
The MGT shows the attitude towards treatment, the
BT shows the understanding of the illness and the refer-
ence method informs us about the action of taking the
treatment. We think that the measures of adherence all
assess the same behaviour, though with a few differ-
ences, i.e., the focus, the question itself and the different
components of behaviour. These differences could, we
believe, explain the poor magnitude for agreement.
T h ed i a g n o s t i cv a l i d i t yi n d i c a t o r so b t a i n e db yt h e
other two self-reported methods (MGT and BT) consid-
ered independently show a sensitivity and specificity
fluctuating between 33.33% and 66.66% for the MGT
and between 47% and 69% for the BT. These values
changed when we considered both tests together (both
tests classify the patient as non-adherent), observing a
considerable increase in the specificity, which varied
between 86% and 94%, with a reduction in sensitivity
(13-47%). These values match those of other trials for
chronic diseases, in which the specificity surpasses sensi-
tivity [24,25]. In our case this means that we would clas-
sify correctly adherent subjects (true negative) because
sensitivity is low and specificity is high. In clinical prac-
tice this is very useful because when you use both tests
with a patient and he or she is classified as adherent
you can be sure that this is the case.
If we consider the likelihood ratio to detect non-
adherent patients we see that it varied between 2.84 at
V1 and 7.98 at V2 (when the non-adherence prevalence
was 21%), which means that when the result of both
tests identifies a patient as non-adherent with the sched-
uled inhaled treatment, it is nearly 8-fold more likely to
be a true positive value. At V3 (when the non-adherence
prevalence was 16%), the likelihood ratio decreased to
1.77. This result suggests that there is a critical point of
non-adherence prevalence below which the tests lose
their ability to detect non-adherent behaviour with suffi-
cient reliability.
Considering all the results of the study, we propose a
practical approach to assess self-adherence in clinical
practice that depends on the expected adherence
prevalence:
- If we expect a high or medium non-adherence pre-
valence in our clinical setting, we can use the self-
reported methods (MGT and BT together) to detect
and to follow-up the non-adherent patients. We can
thus detect non adherence in a simple and rapid
manner.
- If we expect a low non-adherence prevalence, we
can use the dose/pill count or EM for MDI devices.
Conclusion
Despite the fact that methods to measure adherence are
not perfect, it is better to use them in a homogeneous
and structured manner rather than not to take them
into account. The dose/pill count could be chosen in
clinical practice, even though we know that it overesti-
mates adherence. An alternative to the dose/pill or EM
count is a self-reported method, but the diagnostic
validity of the two tests performed independently is low.
Nevertheless, when they are considered together they
have a higher potential to detect patients with non-
adherence to therapeutic regimens and at a low cost.
Despite the limitations of this study, we nevertheless
consider that it gives us more information with which
to improve the quantitative evaluation of adherence by
the COPD patient. However, an important problem still
remains to be resolved: the incorrect use of the different
inhaler devices, even in compliant patients, in whom it
should also be evaluated.
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